Please Wait
Applying Filters...
menu
    • menu
    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Together we can improve the quality of life

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Lisaftoclax

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ascentage Pharma Shares Innovation Strategy at J.P. Morgan Conf
    Ascentage Pharma Shares Innovation Strategy at J.P. Morgan Conf

    14 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/15/3219202/0/en/Ascentage-Pharma-Outlined-its-Global-Innovation-Strategy-During-Presentation-at-44th-Annual-J-P-Morgan-Healthcare-Conference.html

    GLOBENEWSWIRE
    14 Jan 2026
    Share Share
    Ascentage Pharma Reveals Positive Results From Lisaftoclax Study
    Ascentage Pharma Reveals Positive Results From Lisaftoclax Study

    07 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/08/3201167/0/en/ASH-2025-Ascentage-Pharma-Presents-Encouraging-Data-from-Phase-Ib-II-Study-of-Bcl-2-Inhibitor-Lisaftoclax-in-Venetoclax-Exposed-Patients-with-Myeloid-Malignances.html

    GLOBENEWSWIRE
    07 Dec 2025
    Share Share
    Ascentage Pharma Presents Lisaftoclax Data at ASH Meeting 2025
    Ascentage Pharma Presents Lisaftoclax Data at ASH Meeting 2025

    06 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/06/3201070/0/en/Ascentage-Pharma-Presents-Pivotal-China-Registrational-Study-Data-for-Lisaftoclax-in-Oral-Report-at-2025-American-Society-of-Hematology-ASH-Annual-Meeting.html

    GLOBENEWSWIRE
    06 Dec 2025
    Share Share
    Ascentage Pharma To Present Lisaftoclax Clinical Study Data
    Ascentage Pharma To Present Lisaftoclax Clinical Study Data

    03 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/04/3179927/0/en/Ascentage-Pharma-to-Present-Data-from-Two-Clinical-Studies-for-Bcl-2-Inhibitor-Lisaftoclax-Including-an-Oral-Report-at-ASH-2025.html

    GLOBENEWSWIRE
    03 Nov 2025
    Share Share
    Ascentage’s Lisaftoclax Ph3 Study in Myelodysplastic Get Approval
    Ascentage’s Lisaftoclax Ph3 Study in Myelodysplastic Get Approval

    17 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/17/3134672/0/en/Ascentage-Pharma-Announces-Global-Registrational-Phase-III-Study-of-Lisaftoclax-for-First-line-Treatment-of-Patients-with-Higher-Risk-Myelodysplastic-Syndrome-Cleared-by-US-FDA-and.html

    GLOBENEWSWIRE
    17 Aug 2025
    Share Share
    China NMPA Approves Ascentage Pharma's Lisaftoclax
    China NMPA Approves Ascentage Pharma's Lisaftoclax

    10 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/10/3113419/0/en/Ascentage-Pharma-Announces-Its-Novel-Bcl-2-Inhibitor-Lisaftoclax-Approved-by-China-NMPA-Ushering-in-a-New-Era-for-the-Treatment-of-CLL-SLL.html

    GLOBENEWSWIRE
    10 Jul 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.